{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T03:04:05Z","timestamp":1776999845565,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Molecular pathology is an essential part of pathology complementing conventional morphological tools to obtain a correct integrated diagnosis with appropriate assessment of prognosis and prediction of response to therapy, particularly in cancer. There is a concern about the situation of molecular pathology in some areas of Europe, namely, regarding the central role of pathologists in assessing somatic genomic alterations in cancer. In some countries, there are attempts that other laboratory medicine specialists perform the molecular analysis of somatic alterations in cancer, particularly now when next generation sequencing (NGS) is incorporated into clinical practice. In this scenario, pathologists may play just the role of \u201ctissue providers,\u201d and other specialists may take the lead in molecular analysis. Geneticists and laboratory medicine specialists have all background and skills to perform genetic analysis of germline alterations in hereditary disorders, including familial forms of cancers. However, interpretation of somatic alterations of cancer belongs to the specific scientific domain of pathology. Pathologists are necessary to guarantee the quality of the results, for several reasons: (1) The identified molecular alterations should be interpreted in the appropriate morphologic context, since most of them are context-specific; (2) pre-analytical issues must be taken into consideration; (3) it is crucial to check the proportion of tumor cells in the sample subjected to analysis and presence of inflammatory infiltrate and necrosis should be monitored; and 4) the role of pathologists is crucial to select the most appropriate methods and to control the turnaround time in which the molecular results are delivered in the context of an integrated diagnosis. Obviously, there is the possibility of having core facilities for NGS in a hospital to perform the sequence analysis that are open to other specialties (microbiologists, geneticists), but also in this scenario, pathologists should have the lead in assessing somatic alterations of cancer. In this article, we emphasize the importance of interpreting somatic molecular alterations of the tumors in the context of morphology. In this Position Paper of the European Society of Pathology, we strongly support a central role of pathology departments in the process of analysis and interpretation of somatic molecular alterations in cancer.<\/jats:p>","DOI":"10.1007\/s00428-020-02757-0","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T20:02:51Z","timestamp":1583179371000},"page":"491-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology"],"prefix":"10.1007","volume":"476","author":[{"name":"on behalf of the European Society of Pathology (ESP)","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-6605","authenticated-orcid":false,"given":"Xavier","family":"Matias-Guiu","sequence":"first","affiliation":[]},{"given":"Giorgio","family":"Stanta","sequence":"additional","affiliation":[]},{"given":"F\u00e1tima","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"Ales","family":"Ryska","sequence":"additional","affiliation":[]},{"given":"Gerald","family":"Hoefler","sequence":"additional","affiliation":[]},{"given":"Holger","family":"Moch","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"2757_CR1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546\u20131558","journal-title":"Science"},{"key":"2757_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"2757_CR3","doi-asserted-by":"crossref","first-page":"32602","DOI":"10.18632\/oncotarget.5289","volume":"6","author":"SP Patel","year":"2015","unstructured":"Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R (2015) Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget 6:32602\u201332609","journal-title":"Oncotarget"},{"key":"2757_CR4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5858\/133.1.124","volume":"133","author":"GP Pena","year":"2009","unstructured":"Pena GP, de Andrade-Filho JS (2009) How does a pathologist make a diagnosis? Arch Pathol Lab Med 133:124\u2013132","journal-title":"Arch Pathol Lab Med"},{"key":"2757_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/00313020903121887","volume":"41","author":"JR Srigley","year":"2009","unstructured":"Srigley JR (2009) The pathologist as diagnostic oncologist. Pathology. 41:513\u2013514","journal-title":"Pathology."},{"key":"2757_CR6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.5858\/133.4.605","volume":"133","author":"EE Walk","year":"2009","unstructured":"Walk EE (2009) The role of pathologists in the era of personalized medicine. Arch Pathol Lab Med. 133:605\u2013610","journal-title":"Arch Pathol Lab Med."},{"key":"2757_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.molonc.2014.07.021","volume":"8","author":"M Salto-Tellez","year":"2014","unstructured":"Salto-Tellez M, James JA, Hamilton PW (2014) Molecular pathology - the value of an integrative approach. Mol Oncol 8:1163\u20131168","journal-title":"Mol Oncol"},{"key":"2757_CR8","first-page":"1003","volume":"1","author":"DV Parums","year":"2016","unstructured":"Parums DV (2016) The role of pathologist in the era of personalized medicine. SM J Clin Pathol 1:1003","journal-title":"SM J Clin Pathol"},{"key":"2757_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/bies.201100017","volume":"33","author":"J Rodriguez-Canales","year":"2011","unstructured":"Rodriguez-Canales J, Eberle FC, Jaffe ES, Emmert-Buck MR (2011) Why is it crucial to reintegrate pathology into cancer research? Bioessays. 33:490\u2013498","journal-title":"Bioessays."},{"key":"2757_CR10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/nbt0908-978","volume":"26","author":"TA Ince","year":"2008","unstructured":"Ince TA, Ward JM, Valli VE, Sgroi D, Nikitin AY, Loda M, Griffey SM, Crum CP, Crawford JM, Bronson RT, Cardiff RD (2008) Do-it-yourself (DIY) pathology. Nat Biotechnol 26:978\u2013979","journal-title":"Nat Biotechnol"},{"key":"2757_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamaoncol.2015.35","volume":"1","author":"HM Horlings","year":"2015","unstructured":"Horlings HM, Shah SP, Huntsman DG (2015) Using somatic mutations to guide treatment decisions: context matters. JAMA Oncol 1:275\u2013276","journal-title":"JAMA Oncol"},{"key":"2757_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc.2017.5","volume":"17","author":"G Schneider","year":"2017","unstructured":"Schneider G, Schmidt-Supprian M, Rad R, Saur D (2017) Tissue-specific tumorigenesis: context matters. Nat Rev Cancer 17:239\u2013253","journal-title":"Nat Rev Cancer"},{"key":"2757_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrc1674","volume":"5","author":"OM Sieber","year":"2005","unstructured":"Sieber OM, Tomlinson SR, Tomlinson IP (2005) Tissue, cell and stage specificity of (epi)mutations in cancers. Nat Rev Cancer 5:649\u2013655","journal-title":"Nat Rev Cancer"},{"key":"2757_CR14","doi-asserted-by":"publisher","first-page":"20707","DOI":"10.1038\/srep20707","volume":"6","author":"MH Schaefer","year":"2016","unstructured":"Schaefer MH, Serrano L (2016) Cell type-specific properties and environment shape tissue specificity of cancer genes. Sci Rep 6:20707","journal-title":"Sci Rep"},{"key":"2757_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/2159-8290.CD-12-0018","volume":"2","author":"S Chandarlapaty","year":"2012","unstructured":"Chandarlapaty S (2012) Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov 2:311\u2013319","journal-title":"Cancer Discov"},{"key":"2757_CR16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.molonc.2014.03.004","volume":"8","author":"HJ Dubbink","year":"2014","unstructured":"Dubbink HJ, Deans ZC, Tops BB, van Kemenade FJ, Koljenovi\u0107 S, van Krieken HJ, Blokx WA, Dinjens WN, Groenen PJ (2014) Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe. Mol Oncol 8:830\u2013839","journal-title":"Mol Oncol"},{"key":"2757_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000469664","volume":"85","author":"FT Bosman","year":"2018","unstructured":"Bosman FT (2018) Tumor heterogeneity: will it change what pathologists do. Pathobiology. 85:18\u201322","journal-title":"Pathobiology."},{"key":"2757_CR18","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.14694\/EDBK_158930","volume":"35","author":"S Venkatesan","year":"2016","unstructured":"Venkatesan S, Swanton C (2016) Tumor evolutionary principles: how Intratumor heterogeneity influences Cancer treatment and outcome. Am Soc Clin Oncol Educ Book 35:e141\u2013e149","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2757_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/his.12993","volume":"70","author":"J Griffin","year":"2017","unstructured":"Griffin J, Treanor D (2017) Digital pathology in clinical use: where are we now and what is holding us back? Histopathology. 70:134\u2013145","journal-title":"Histopathology."},{"key":"2757_CR20","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1016\/S1470-2045(19)30154-8","volume":"20","author":"MKK Niazi","year":"2019","unstructured":"Niazi MKK, Parwani AV, Gurcan MN (2019) Digital pathology and artificial intelligence. Lancet Oncol 20:e253\u2013e261","journal-title":"Lancet Oncol"},{"key":"2757_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00428-016-2000-3","volume":"469","author":"L Bubendorf","year":"2016","unstructured":"Bubendorf L, B\u00fcttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, L\u00f3pez-R\u00edos F, Marchetti A, \u00d6z B, Pauwels P, Penault-Llorca F, Rossi G, Ry\u0161ka A, Thunnissen E (2016) Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch 469:489\u2013503","journal-title":"Virchows Arch"},{"key":"2757_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrd.2018.6","volume":"17","author":"K Garber","year":"2018","unstructured":"Garber K (2018) Tissue-agnostic cancer drug pipeline grows, despite doubts. Nat Rev Drug Discov 17:227\u2013229","journal-title":"Nat Rev Drug Discov"},{"key":"2757_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731\u2013747","journal-title":"Nat Rev Clin Oncol"},{"key":"2757_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/jclinpath-2018-205679","volume":"72","author":"F Penault-Llorca","year":"2019","unstructured":"Penault-Llorca F, Rudzinski ER, Sepulveda AR (2019) Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol 72:460\u2013467","journal-title":"J Clin Pathol"},{"key":"2757_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12885-018-4023-4","volume":"18","author":"A Ryska","year":"2018","unstructured":"Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, Kovalszky I, Olszewski W, Oz B, Plank L, Timar J (2018) NSCLC molecular testing in Central and Eastern European countries. BMC Cancer 18:269","journal-title":"BMC Cancer"},{"key":"2757_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3109\/10520295.2011.591832","volume":"87","author":"DG Hicks","year":"2012","unstructured":"Hicks DG, Boyce BF (2012) The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research. Biotech Histochem 87:14\u201317","journal-title":"Biotech Histochem"},{"key":"2757_CR27","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.5858\/arpa.2019-0009-SA","volume":"143","author":"CC Compton","year":"2019","unstructured":"Compton CC, Robb JA, Anderson MW, Berry AB, Birdsong GG, Bloom KJ, Branton PA, Crothers JW, Cushman-Vokoun AM, Hicks DG, Khoury JD, Laser J, Marshall CB, Misialek MJ, Natale KE, Nowak JA, Olson D, Pfeifer JD, Schade A, Vance GH, Walk EE, Yohe SL (2019) Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine. Arch Pathol Lab Med 143:1346\u20131363","journal-title":"Arch Pathol Lab Med"},{"key":"2757_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-0500-4-1","volume":"4","author":"D de Jong","year":"2011","unstructured":"de Jong D, Verbeke S, Meijer D, Hogendoorn PC, Bovee JV, Szuhai K (2011) Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples. BMC Res Notes 4:1","journal-title":"BMC Res Notes"},{"key":"2757_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2559.2010.03711.x","volume":"59","author":"PJ Groenen","year":"2011","unstructured":"Groenen PJ, Blokx WA, Diepenbroek C, Burgers L, Visinoni F, Wesseling P, van Krieken JH (2011) Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Histopathology. 59:1\u20137","journal-title":"Histopathology."},{"key":"2757_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/PDM.0b013e3181b520f8","volume":"19","author":"I Dotti","year":"2010","unstructured":"Dotti I, Bonin S, Basili G, Nardon E, Balani A, Siracusano S, Zanconati F, Palmisano S, De Manzini N, Stanta G (2010) Effects of formalin, methacarn, and fineFIX fixatives on RNA preservation. Diagn Mol Pathol 19:112\u2013122","journal-title":"Diagn Mol Pathol"},{"key":"2757_CR31","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s004280100450","volume":"439","author":"E Heinm\u00f6ller","year":"2001","unstructured":"Heinm\u00f6ller E, Renke B, Beyser K, Dietmaier W, Langner C, R\u00fcschoff J (2001) Piffalls in diagnostic molecular pathology--significance of sampling error. Virchows Arch 439:504\u2013511","journal-title":"Virchows Arch"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02757-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-020-02757-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02757-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T01:00:16Z","timestamp":1614646816000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-020-02757-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2757"],"URL":"https:\/\/doi.org\/10.1007\/s00428-020-02757-0","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"assertion":[{"value":"30 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}